Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
Esteban Cruz, Veysel KayserSchool of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaAbstract: Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of a wide range of solid tumors. The targeted nature of these biotherapeutics has improved treatment outcomes...
Guardado en:
Autores principales: | Cruz E, Kayser V |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/47df797738d34ba48a6a75b530a77069 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Antibody Therapies for Large B-Cell Lymphoma
por: Novo M, et al.
Publicado: (2021) -
Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
por: Tan Y, et al.
Publicado: (2021) - Monoclonal antibodies in immunodiagnosis and immunotherapy
-
Photodynamic Priming Improves the Anti-Migratory Activity of Prostaglandin E Receptor 4 Antagonist in Cancer Cells In Vitro
por: Aaron J. Sorrin, et al.
Publicado: (2021) -
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells
por: Xu S, et al.
Publicado: (2018)